Abstract
The bioavailability of a drug depends on the properties of the drug product, a combination of drug and formulation properties. The support for formulation development by means of clinical PK studies is multifaceted and, in fact, covers all routes of administration, intravascular routes as well as extravascular ones, like oral, intramuscular, or subcutaneous routes, and – in most instances – vaginal, dermal, ocular, topic, rectal, nasal, or pulmonary administration. The drugability (disease-tailored exposure profiles mediated by optimized delivery systems) of pharmacologically active substances will remain one of the major challenges in drug development, especially if poorly absorbable, poorly soluble compounds are considered. Rare exceptions include some drugs belonging to BCS class I (highly soluble, highly permeable) that rapidly dissolve from Immediate Release solid oral drug products.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
REFERENCES AND FURTHER READING
CPMP/EWP/560/95 Note for Guidance on the Investigation of Drug Interactions (CPMP, June 1998)
CPMP/EWP/QWP/1401/98 Note for Guidance on the Investigation of Bioavailability and Bioequivalence (CPMP, January 2002)
Guidance for Industry Scale-up and post-approval changes (SUPAC-IR): Chemistry, manufacturing, and control; in vitro dissolution testing and in vivo bioequivalence documentation. U.S. Department of Health and Human Services, Food and Drug Administration; Center for Drug Evaluation and Research (CDER). September 1995
Guidance for Industry Scale-up and post-approval changes (SUPAC-MR): Chemistry, manufacturing, and control; in vitro dissolution testing and in vivo bioequivalence documentation. U.S. Department of Health and Human Services, Food and Drug Administration; Center for Drug Evaluation and Research (CDER). September 1997
Guidance for Industry Statistical Approaches to Establishing Bioequivalence. U.S. Department of Health and Human Services, Food and Drug Administration; Center for Drug Evaluation and Research (CDER). January 2001
Guidance for Industry Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms containing certain active moieties/active ingredients based on the biopharmaceutics classification system (BCS). U.S. Department of Health and Human Services, Food and Drug Administration; Center for Drug Evaluation and Research (CDER). January 1999
Steinijans V-W, Hauschke D (1997) Individual bioequivalence. A European perspective. J Biopharm Stat 7(1):31–34
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Wesch, R. (2011). Specific Studies for Formulation Development. In: Vogel, H.G., Maas, J., Gebauer, A. (eds) Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-89891-7_15
Download citation
DOI: https://doi.org/10.1007/978-3-540-89891-7_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-89890-0
Online ISBN: 978-3-540-89891-7
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences